title: The Randomised Clinical Trial and the Hazard Ratio - medical research's Emperor's New Clothes?
abstract: As the enthusiasm for individualized treatment and targeted therapies continues to gain momentum, it seems timely to re-assess whether our current research tools are fit for purpose. Randomized Clinical Trials compare groups of patients, the Hazard Ratio is a 'group summary statistic', and modeling shows that the same Hazard Ratio score could result from a number of scenarios. Thus the current tools do not provide definitive information as to how to treat an individual patient. We therefore need to concentrate on the use of predictive factor analyses to identify the characteristics of subgroups of patients who respond to specific treatments.
authors.affiliation: Retired, previously MRC Clinical Trials Unit, London, UK. richardjamesstephens@gmail.com.
authors.forename: Richard
authors.initials: R
authors.lastname: Stephens
authors.forename: David
authors.initials: D
authors.lastname: Stewart
mesh_terms: D035843:Biomedical Research; D006801:Humans; D058990:Molecular Targeted Therapy; D057285:Precision Medicine; D016032:Randomized Controlled Trials as Topic
references.citation: BMC Cancer. 2013 Apr 16;13:193
references.pmid: 23587187